Stress ulcers: prophylaxis and treatment


Cite item

Full Text

Abstract

Stress ulcers (SU) are the problem of serious patients treated in intensive care unit. The key pathogenic mechanisms of SU are the blood flow reduction in the gastric mucosa and acidopeptic aggression. The authors prefer proton pump inhibitors with low drug interactions level, lack of cumulative effect and the availability of dosage forms for parenteral and oral administration in the prevention and treatment of SU. In particular, the drug pantoprazole (Controloc) has these properties. Prevention of stress erosive and ulcerative lesions includes intravenous Conroloc administration with subsequent transition to oral drug administration. Prophylactic treatment reduces the incidence of SU and bleeding, improves the survival rate of serious patients.

References

  1. Wilcox CM, Spenney JG. Stress ulcer prophylaxis in medical patients: who, what, and how much. Am J Gastroenterol 1988;83(11):1199-211.
  2. Гельфанд Б.Р., Гурьянов А.В., Мартынов А.Н. и др. Профилактика стресс - повреждений желудочно-кишечного тракта у больных в критических состояниях // Consilium medicum. 2005. Т. 7. № 6. С. 464-7.
  3. Fennerty M.B. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med 2002;30:S351-5.
  4. Skillman JJ, Bushnell LS, Goldman H, et al. Respiratory failure, hypotension, sepsis and jaundice: A clinical syndrome associated with lethal hemorrhage from acute stress ulceration of the stomach. Am J Surg 1969;117:523-30.
  5. Di Fiore F, Lecleire S, Merle V, et al. Changes in characteristics and outcome of acute upper gastrointestinal haemorrhage: a comparison of epidemiology and practices between 1996 and 2000 in a multicentre French study. Eur J Gastroenterol Hepatol 2005;17:641-7.
  6. Яковенко А.В., Григорьев П.Я., Яковенко Э. П. и др. Цитопротекторы в терапии заболеваний желудка. Оптимальный подход к выбору препарата // Клиническая и экспериментальная гастроэнтерология. 2006. № 2. С. 56-60.
  7. Whittle BJR. Protective mechanisms of the gastric mucosa / Gustavsson S., Kumar D., Graham D.Y. (eds). The stomach. - Edinburgh, London, Madrid: Churchill Livingstone 1992:81-101.
  8. Powell DW. Physiological concepts of epithelial barriers / Allen A. (Ed.)
  9. Mechanisms of mucosal protection in the upper gastrointestinal tract. New York: Raven Press 1984:1-6.
  10. Никода В.В, Хартукова Н.Е. Применение ингибиторов протонной помпы в интенсивной терапии и реанимации // Фарматека. 2008. № 6. С. 9-15.
  11. Harjola P, Sivula A. Gastric ulceration following experimentally induced hypoxia and hemorrhagic shock: In vivo study of pathogenesis in rabbits. Ann Surg 1966;163:21-8.
  12. Mersereau WA, Hinchey EJ. Effect of gastric acidity on gastric ulceration induced by hemorrhage in the rat, utilizing a gastric chamber technique. Gastroenterology 1973;64:1130-35.
  13. Arabehety JT, Dolcini H, Grey SJ. Sympathetic influences on the circulation of the gastric mucosa of the rat. Am J Physiol 1959;197:915-22.
  14. Moody FG, Aldrete JS. Hydrogen permeability of canine gastric secretory epithelium during formation of acute superficial erosions. Surgery 1971;70:154-60.
  15. Zinner MJ, Turtinen L, Gurll NJ. The role of acid and ischemia in production of stress ulcers during canine hemorrhagic shock. Surgery 1975;77:807-16.
  16. Ritchie WP. Acute gastric mucosal damage induced by bile salts, acid, and ischemia. Gastroenterology 1975;68:699-707.
  17. Ritchie WP. Prostaglandins: A surgeon's perspective. Dig Dis Sci l986;31:S.32-4.
  18. Яковенко Э.П., Яковенко А.В., Агафонова Н.А. и др. Пептические язвы, патогенетические подходы к терапии // Фарматека. 2008. № 6. С. 62-67.
  19. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006;25(1):CD002094.
  20. Morris J, Karlstadt R, Blatcher D, et al. Intermittent intravenous pantoprazole rapidly achieves and maintains gastric pH > 4,0 compared with continuous infusion H2-receptor antagonist in intensive care unit patients [abstract]. Crit Care Med 2001;29:A147.
  21. Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996;34(5):185-94.
  22. Andersson T, Cederberg C, Heggelund A. The pharmacokinetics of single and repeated once daily dose of 10, 20 and 40 mg omeprazole as enteric coated granules. Drug Invest 1991;3:45-52.
  23. Bliesath H, Huber R, Hartmann M, et al. Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration. Int J Clin Pharmacol Ther 1994;32(1):44-50.
  24. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs 1997;54:581-96.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies